Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O00238
UPID:
BMR1B_HUMAN
Alternative names:
-
Alternative UPACC:
O00238; B2R953; B4DSV1; P78366
Background:
The Bone morphogenetic protein receptor type-1B plays a pivotal role in skeletal development and repair, mediating cellular responses to growth factors. It is integral in the signaling pathway that influences chondrocyte differentiation and bone formation.
Therapeutic significance:
Linked to Acromesomelic dysplasia 3, Brachydactyly A2, and Brachydactyly A1, D, this receptor's genetic variants underscore its critical role in limb development. Targeting its pathway offers a promising avenue for correcting skeletal malformations.